Survival according to tertiles of copeptin.

<p>Survival according to tertiles of copeptin in the total cohort (A), in medical patients (B) and in patients that were admitted due to cardiac surgery or heart valve intervention (C);</p

Copeptin serum levels and 30 day survival.

<p>Serum levels of copeptin in 30-day survivors and non-survivors in the total cohort (A), in medical patients (B) and in patients that were admitted because of cardiac surgery or heart valve intervention (C); outliers not shown; * p<0.05; ¶ p<0.005</p

Clinical and demographic baseline characteristics of the study population.

<p>Clinical and demographic baseline characteristics of the study population.</p

Cox proportional hazard model assessing the risk for mortality according to sST2 levels.

<p>sST2 denotes soluble ST2, CAD denotes coronary artery disease, BMI denotes body mass index.</p

Relation of sST2 serum levels to mortality.

<p>sST2 serum levels were measured as described under “Methods”. Kaplan Meier survival curves for the highest quintile of sST2 serum levels (red, dashed line) vs. the lower four quintiles of sST2 (blue, full line) in all patients (A), patients with ST-elevation myocardial infarction (B), non-ST-elevation myocardial infarction (C) and stable angina (D).</p

sST2 and IL-33 serum levels in controls and according clinical presentation of coronary artery disease.

<p>sST2 (A) and IL-33 (B) serum levels were measured as described under “Methods”. SA denotes stable angina, NSTEMI denotes non-ST-elevation myocardial infarction, STEMI denotes ST-elevation myocardial infarction. Mean ± standard error of mean.</p

Baseline characteristics of study population.

<p>SA denotes stable angina, NSTEMI denotes non-ST-elevation myocardial infarction, STEMI denotes ST-elevation myocardial infarction, CAD denotes coronary artery disease, BMI denotes body mass index.</p

Relation of IL-33 serum levels to mortality.

<p>IL-33 serum levels were measured as described under “Methods”. Kaplan Meier survival curves for the highest quintile of IL-33 serum levels (red, dashed line) vs. the lower four quintiles of IL-33 (blue, full line) in all patients (A), patients with ST-elevation myocardial infarction (B), non-ST-elevation myocardial infarction (C) and stable angina (D).</p

Angiographical and interventional characteristics of patients with and without combined endpoint during follow-up period.

<p>MACE: major adverse cardiac cardiovascular events (death, myocardial infarction, rehospitalisation); CAD: coronary artery disease; BMS: bare metal stent; DES: drug eluting stent.</p><p>Angiographical and interventional characteristics of patients with and without combined endpoint during follow-up period.</p

Multivariate Cox proportional hazards model assessing the association between G-CSF (below and above median) and major adverse cardiovascular events (death, myocardial infarction and rehospitalisation).

<p><b>-</b> denotes reference category.</p><p>Multivariate Cox proportional hazards model assessing the association between G-CSF (below and above median) and major adverse cardiovascular events (death, myocardial infarction and rehospitalisation).</p